PharmaDrug narrows list of candidate tryptamine molecules for the treatment of primary open angle glaucoma (PAOG) Terasaki Institute receives PharmaDrug’s two candidate DMT analogue molecules Terasaki Institute, initiates supportive IND-enabling mechanism of action studies to evaluate potency and kinetics of PharmaDrug’s DMT analogues Toronto, Ontario–(Newsfile Corp. – November 5, 2021)…


Previous articleMindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
Next articlePsychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to Rick Doblin